Baudax Bio, Inc.
Baudax Bio, Inc.
Share · US07160F4046 · BXRX (XNAS)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 0,00 % -100,00 %

Company Profile for Baudax Bio, Inc. Share

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Company Data

Name Baudax Bio, Inc.
Company Baudax Bio, Inc.
Symbol BXRX
Website https://www.baudaxbio.com
Primary Exchange XNAS NASDAQ
ISIN US07160F4046
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Geraldine A. Henwood Ph.D.
Country United States of America
Currency USD
Employees 0,0 T
Address 490 Lapp Road, 19355 Malvern
IPO Date 2019-11-14

Ticker Symbols

Name Symbol
NASDAQ BXRX

More Shares

Investors who Baudax Bio, Inc. hold also have the following shares in their portfolio:
Invesco S&P SmallCap Energy ETF
Invesco S&P SmallCap Energy ETF ETF
LYXOR CORE GLOBAL GOVERNMENT BOND (DR) UCITS ETF - MONTHLY HEDGED TO EUR - DIST
LYXOR CORE GLOBAL GOVERNMENT BOND (DR) UCITS ETF - MONTHLY HEDGED TO EUR - DIST ETF
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025